Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy
Chun-Lai Ma1, Zheng Jiao1, Xun-Yi Wu2
1Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Pharmacogenomics
|August 29, 2015
Summary
Genetic variations in SCN1A and EPHX1 influence carbamazepine (CBZ) treatment. Specific alleles require higher CBZ doses and affect drug concentrations, impacting personalized medicine approaches.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Molecular Biology
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Individual variability in CBZ response necessitates understanding genetic influences on its pharmacokinetics and pharmacodynamics (PK/PD).
- Identifying genetic markers can optimize CBZ dosing and improve therapeutic outcomes.
Purpose of the Study:
- To investigate the association between key genetic variants affecting CBZ PK/PD and the drug's maintenance dosage and serum concentrations.
- To explore potential gene-gene interactions influencing CBZ treatment.
Main Methods:
- Genotyping of 166 patients on CBZ monotherapy using high-resolution melting curve (HRM) and TaqMan assays.
- Statistical analyses including univariate and multiple regression to assess genotype-phenotype correlations.
Main Results:
- Carriers of SCN1A IVS5-91G>A or EPHX1 c.337T>C alleles required higher CBZ doses.
- These genetic variants were associated with a lower CBZ natural logarithmic concentration-dose ratio (lnCDR).
- Significant gene-gene interactions were observed for lnCDR and CBZ maintenance dosage.
Conclusions:
- The SCN1A IVS5-91G>A gene polymorphism is a potential genetic biomarker for predicting carbamazepine pharmacokinetics.
- These findings contribute to the development of personalized pharmacogenetic approaches for CBZ therapy.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
118
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
118
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
180
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
180
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
83
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
83
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:16Drug toxicity: Idiosyncratic Reactions
171
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
171